"Anti-HIV Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS.
| Descriptor ID |
D019380
|
| MeSH Number(s) |
D27.505.954.122.388.077.088
|
| Concept/Terms |
Anti-HIV Agents- Anti-HIV Agents
- Agents, Anti-HIV
- Anti HIV Agents
- Anti-AIDS Agents
- Agents, Anti-AIDS
- Anti AIDS Agents
- Anti-HIV Drugs
- Anti HIV Drugs
- Drugs, Anti-HIV
- AIDS Drugs
- Drugs, AIDS
- Anti-AIDS Drugs
- Anti AIDS Drugs
- Drugs, Anti-AIDS
|
Below are MeSH descriptors whose meaning is more general than "Anti-HIV Agents".
Below are MeSH descriptors whose meaning is more specific than "Anti-HIV Agents".
This graph shows the total number of publications written about "Anti-HIV Agents" by people in this website by year, and whether "Anti-HIV Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 0 | 1 |
| 1999 | 2 | 3 | 5 |
| 2000 | 4 | 2 | 6 |
| 2001 | 3 | 0 | 3 |
| 2002 | 3 | 7 | 10 |
| 2003 | 1 | 4 | 5 |
| 2004 | 5 | 4 | 9 |
| 2005 | 2 | 3 | 5 |
| 2006 | 1 | 1 | 2 |
| 2007 | 8 | 4 | 12 |
| 2008 | 7 | 2 | 9 |
| 2009 | 3 | 4 | 7 |
| 2010 | 3 | 9 | 12 |
| 2011 | 7 | 1 | 8 |
| 2012 | 10 | 5 | 15 |
| 2013 | 9 | 7 | 16 |
| 2014 | 6 | 3 | 9 |
| 2015 | 7 | 4 | 11 |
| 2016 | 6 | 5 | 11 |
| 2017 | 9 | 5 | 14 |
| 2018 | 11 | 5 | 16 |
| 2019 | 4 | 2 | 6 |
| 2020 | 11 | 3 | 14 |
| 2021 | 7 | 1 | 8 |
| 2022 | 5 | 0 | 5 |
| 2023 | 6 | 0 | 6 |
| 2024 | 6 | 2 | 8 |
To return to the timeline,
click here.
Below are the most recent publications written about "Anti-HIV Agents" by people in Profiles.
-
Provider Factors Likely to Impact Access and Uptake of Long-Acting Injectable Cabotegravir for Transgender Women in the United States: Results of a Qualitative Study. J Assoc Nurses AIDS Care. 2024 Sep-Oct 01; 35(5):437-449.
-
Willingness to trade-off years of life for an HIV cure - an experimental exploration of affective forecasting. AIDS Res Ther. 2024 Aug 06; 21(1):51.
-
Resistance-informed versus empirical management of viraemia in children and adolescents with HIV in Lesotho and Tanzania (GIVE MOVE trial): a multisite, open-label randomised controlled trial. Lancet Glob Health. 2024 Aug; 12(8):e1312-e1322.
-
Impact of efavirenz on hormone-positive breast cancer survival in women living with HIV. AIDS. 2024 07 15; 38(9):1439-1442.
-
Predicting mortality within 1 year of ART initiation in children and adolescents living with HIV in sub-Saharan Africa: a retrospective observational cohort study. Lancet Glob Health. 2024 Jun; 12(6):e929-e937.
-
Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study. Lancet HIV. 2024 Apr; 11(4):e211-e221.
-
Variable antiviral activity of islatravir against M184I/V mutant HIV-1 selected during antiretroviral therapy. J Antimicrob Chemother. 2024 02 01; 79(2):370-374.
-
Antiretroviral Therapy in Pregnancy: A 2023 Review of the Literature. Curr HIV/AIDS Rep. 2024 02; 21(1):1-10.
-
Factors associated with the acceptability of Lopinavir/Ritonavir formulations among children living with HIV/AIDS attending care and treatment clinics in Mbeya and Mwanza, Tanzania. PLoS One. 2024; 19(1):e0292424.
-
Antiviral potency of long-acting islatravir subdermal implant in SHIV-infected macaques. J Control Release. 2024 02; 366:18-27.